Transparency in Medical Device Applicability Determinations in Japan: An Empirical Analysis of Administrative Consultation Records and Policy Implications.
- 1Graduate School of Medicine, Hirosaki University, Hirosaki, Japan.
Abstract
Background
Determining whether a product qualifies as a medical device is a fundamental step in medical device regulation because it defines the scope of regulatory requirements, including approval, advertising restrictions, and market access. In Japan, these determinations are based not only on statutory provisions but also on administrative notices, Q&A documents, and intergovernmental consultations. However, the transparency of the underlying decision-making process has received limited empirical investigation.Methods
This qualitative single-case study analyzed 10 administrative records covering July 7 to November 11, 2025, and combined legal analysis, thematic analysis of administrative consultation records and written responses obtained through freedom of information requests, and international comparison with regulatory frameworks in the United States, the European Union, the World Health Organization (WHO), and the International Medical Device Regulators Forum (IMDRF).Results
Medical device applicability determinations in Japan relied extensively on product labeling, advertising claims, intended use, and soft-law instruments, including administrative notices and consultation records. Although this consultation-based approach provides flexibility in responding to emerging technologies such as artificial intelligence (AI)-based medical devices and Software as a Medical Device (SaMD), the legal reasoning and decision-making criteria were not always publicly available. The documentary comparison identified public guidance and regulatory information mechanisms in the United States and the European Union that offer examples for transparency policy design; it did not establish a jurisdiction-wide ranking of transparency or predictability.Conclusion
Greater transparency in medical device applicability determinations could improve regulatory predictability while preserving the flexibility necessary for case-specific regulatory decisions. Publishing anonymized consultation cases, standardizing explanations of regulatory decisions, and expanding access to regulatory information may strengthen accountability, support responsible innovation, and reinforce public trust. These findings contribute to the literature on regulatory science, health policy, and evidence-informed regulatory governance for emerging medical technologies.
Related
- Global trends and thematic evolution in online consultation with digital health technologies: Implications for future implementation and policy development
- Timing of Addiction Consultation and Alcohol Withdrawal Management in Hospitalized Adults
- Consultation with cardiologists for persons with new-onset chronic heart failure: A population-based study
- Multidimensional evaluation of generative AI chatbots for public consultation on sudden cardiac death: safety, accuracy, empathy, reliability, quality, and readability across six models
- MRSA Knowledge, Infection-Prevention Practices, and Antibiotic Use Without Clinician Consultation Among Hajj Pilgrims Arriving in Madinah, Saudi Arabia: A Cross-Sectional Study †
BibTeX
@article{nakata2026transparency,
title = {{Transparency in Medical Device Applicability Determinations in Japan: An Empirical Analysis of Administrative Consultation Records and Policy Implications.}},
author = {Takanari Nakata},
journal = {Medical devices (Auckland, N.Z.)},
year = {2026},
month = oct,
doi = {10.2147/mder.s642378},
url = {https://europepmc.org/article/MED/42904130},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Transparency in Medical Device Applicability Determinations in Japan: An Empirical Analysis of Administrative Consultation Records and Policy Implications.
AU - Takanari Nakata
PY - 2026
DA - 2026/10/16
JO - Medical devices (Auckland, N.Z.)
DO - 10.2147/mder.s642378
UR - https://europepmc.org/article/MED/42904130
AB - Background Determining whether a product qualifies as a medical device is a fundamental step in medical device regulation because it defines the scope of regulatory requirements, including approval, advertising restrictions, and market access. In Japan, these determinations are based not only on statutory provisions but also on administrative notices, Q&A documents, and intergovernmental consultations. However, the transparency of the underlying decision-making process has received limited empirical investigation.Methods This qualitative single-case study analyzed 10 administrative records covering July 7 to November 11, 2025, and combined legal analysis, thematic analysis of administrative consultation records and written responses obtained through freedom of information requests, and international comparison with regulatory frameworks in the United States, the European Union, the World Health Organization (WHO), and the International Medical Device Regulators Forum (IMDRF).Results Medical device applicability determinations in Japan relied extensively on product labeling, advertising claims, intended use, and soft-law instruments, including administrative notices and consultation records. Although this consultation-based approach provides flexibility in responding to emerging technologies such as artificial intelligence (AI)-based medical devices and Software as a Medical Device (SaMD), the legal reasoning and decision-making criteria were not always publicly available. The documentary comparison identified public guidance and regulatory information mechanisms in the United States and the European Union that offer examples for transparency policy design; it did not establish a jurisdiction-wide ranking of transparency or predictability.Conclusion Greater transparency in medical device applicability determinations could improve regulatory predictability while preserving the flexibility necessary for case-specific regulatory decisions. Publishing anonymized consultation cases, standardizing explanations of regulatory decisions, and expanding access to regulatory information may strengthen accountability, support responsible innovation, and reinforce public trust. These findings contribute to the literature on regulatory science, health policy, and evidence-informed regulatory governance for emerging medical technologies.
SN - 1179-1470
ER -